Statins, as the cornerstone of dyslipidemia management, reduce circulating and intracellular cholesterol levels, but this reduction also leads to the upregulation of sterol regulatory element-binding protein 2 (SREBP-2) and PCSK9 [21–24]. This evidence concerns the gene SREBF2 and metabolic syndrome.